Impact of Automated Blood Culture Systems on the Management of Bloodstream Infections: Results from a Crossover Diagnostic Clinical Trial

Ana Verónica Halperin,a,b Juan Antonio del Castillo Polo,a,b José Luis Cortes-Cuevas,a,b María José Cardenas Isasi,a,b Mario Ampuero Morisaki,a,b Robert Birch,5 Ana María Sánchez Díaz,a,b Rafael Cantóna,b,d

ABSTRACT Bloodstream infections are associated with high rates of morbidity and mortality. Blood culture remains the gold standard for the diagnosis of BSIs. We report a prospective crossover diagnostic clinical trial comparing the performances of two blood culture incubation systems: Virtuo and Bactec FX. The primary outcome was the time to detection (TTD) (from the loading of the sample into the incubator to the positivity signal). Patients over 16 years old suspected of having bacteremia/fungemia were included. They were divided into two strata with a total of 9,957 blood extractions. Initially, each stratum was randomly assigned to one of the incubators and then alternated every 2 weeks for 6 months. Each sample was inoculated into an aerobic bottle and an anaerobic bottle. All bottles were processed equally according to the laboratory’s standard procedures after they were flagged positive. We analyzed 4,797 samples in the Virtuo system and 5,160 in the Bactec FX system. The median TTD was significantly lower for the Virtuo group (Virtuo, 15.2 h; Bactec FX, 16.3 h [P < 0.0001]). The turnaround time (TAT) (from sample loading to the Gram stain report) was also reduced with Virtuo (Virtuo, 26.2 h; Bactec FX, 28.3 h [P < 0.004]). When considering only samples from patients with antimicrobial treatment prior to blood culture extraction, the TTD was shorter for Virtuo (median differences in the TTD of 4.5 h for all bottles and 8.7 h for aerobic bottles only [P = 0.0001]). In conclusion, virtuo provided shorter TTD and TAT than Bactec FX. The difference in the median TTD was increased when considering samples incubated in aerobic bottles from patients with antimicrobial treatment. This could have an important effect on the faster diagnosis of BSIs.

IMPORTANCE Bloodstream infections are associated with high rates of morbidity and mortality. Blood culture remains the gold standard for its diagnosis. While the identification of the pathogen and its antibiotic susceptibility is required to confirm the optimal antimicrobial regimen, reductions in the times to the detection of positivity and reporting of Gram stain results may be important and time-saving to reduce inappropriate antimicrobial use, improve patient outcomes, and decrease health care costs. We report the first clinical diagnostic study of this scale in a “real-world” setting with a crossover design, comparing two automatic blood culture incubators using samples from patients with a suspected diagnosis of bacteremia/sepsis, as opposed to spiked vials. Our study design mimics that of clinical trials performed for drug marketing authorization, but patient randomization was replaced with the crossover design. A shorter time to detection could have an important effect on the faster identification of causative microorganisms of BSIs and antimicrobial stewardship.

KEYWORDS blood culture, clinical diagnostic trial, time to detection, turnaround time
Throughout the world, the number of patients at risk of bloodstream infections (BSIs) continues to rise (1, 2). BSIs are associated with high rates of morbidity and mortality and markedly increase the costs of hospital care. Furthermore, there is a persistent impaired quality of life and higher rates of long-term mortality among hospital survivors after septic shock (3, 4). The prompt identification of the causative agent(s) and the rapid initiation of appropriate antimicrobial therapy are critical for reducing mortality, especially in patients with septic shock (5, 6). Blood culture (BC) remains the gold standard for the diagnosis of BSIs (7).

Over the decades, improvements in BC media combined with the availability of automated growth detection have enhanced the recovery of bloodstream pathogens and decreased the time to detection (TTD) of bacterial growth. Various continuously monitored BC systems, based on colorimetric (BacT/Alert; bioMérieux, Marcy l’Etoile, France) or fluorescence (Bactec; Becton, Dickinson Instrument Systems, Sparks, MD, USA) detection of CO₂ produced by replicating microorganisms, are used extensively in clinical microbiology laboratories to detect the causative agent(s) of BSIs. Both systems employ resin-containing media in BC bottles (i.e., BacT/Alert FAN Plus or Bactec FX Plus) to enhance organism recovery. Most clinical laboratories commonly pair aerobic and anaerobic BC bottles to better recover the vast array of blood pathogens.

In the context of BSIs, while the identification of the pathogen and its antibiotic susceptibility is required to confirm the optimal antimicrobial regimen, reductions in the TTD and the reporting of Gram stain results may be important and time-saving to reduce inappropriate antimicrobial use, improve patient outcomes, and decrease health care costs. A study examining the impact of clinical microbiology laboratory services on the management of clinically significant BSIs found that 75% of antimicrobial regimen initiations took place following the Gram stain report from a positive BC and that notification to the clinician of such results had a greater impact on antimicrobial usage than the provision of antimicrobial susceptibility testing (AST) results (8). In addition, the implementation of targeted antibiotic therapy has been demonstrated to be directly associated with the time required to obtain results; modifications to antibiotic regimens are less likely to occur when the time to results is longer (9). Consequently, faster reporting of positive blood culture results is critical for optimal patient management and reduced health care costs.

Here, we report the results of a prospective crossover diagnostic clinical trial that compared the performances of two different blood culture incubation systems in a real-life setting (BacT/Alert Virtuo and Bactec FX) with patient samples from a tertiary hospital with a 24/7 microbiology laboratory. The primary outcome was the TTD. The secondary outcomes were the turnaround time (TAT) and hands-on-time performance. To our knowledge, this is the first time that this approach has been used to compare two diagnostic systems.

RESULTS
We analyzed a total of 9,957 extractions, 4,797 in the Virtuo arm and 5,160 in the Bactec FX arm (9,538 and 10,204 bottles, respectively).

The median age of the population was 67 years (interquartile ranges [IQRs], 55 to 83 years for Virtuo and 53 to 83 years for Bactec FX) for both groups, and the origins of the samples were similarly distributed for each incubator (emergency department [ED] 90.7% in the Virtuo group and 87% in the Bactec FX group). In the Virtuo group, 926 (53%) of the subjects were male, while in the Bactec group, 1,049 were male (55.8%) (P = 0.0917). The numbers of blood cultures with at least one positive extraction were 874 (18.2%) for Virtuo and 799 (15.5%) for Bactec FX (P = 0.0003), including false-positive results (Virtuo, 20; Bactec FX, 17). Differences in the detection of significant microorganisms when excluding contaminants were not statistically significant between the groups (P = 0.052). For significant microorganisms only, the proportion of anaerobic bottles to be flagged positive first was no different between groups (Virtuo, 5.5%; Bactec FX, 5.8% [P = 0.45]); however, it was larger in the Virtuo group for aerobic
bottles (Virtuo, 5.0%; Bactec FX, 3.6% \( P = 0.0005 \)). The distribution of the samples is shown in Fig. 1.

Overall, the median TTD per blood culture extraction, including all bottle types, was significantly shorter in the Virtuo group (Table 1 and Fig. 2). The TTD was also shorter in the Virtuo arm when analyzing significant organisms and contaminant results separately (Table 1). The difference in the TTD was greatest for aerobic bottles incubated in the Virtuo system, with reductions in the median TTD of 3.7 h and 4.1 h for significant organisms and contaminants, respectively. Even though the TTD was shorter for all positive anaerobic bottles incubated in the Bactec FX system, this difference did not reach statistical significance.

Table 2 summarizes the TTD and TAT by patient characteristics and microorganisms. The median TAT was reduced by 2.1 h for samples incubated in the Virtuo system \( P = 0.004 \). For aerobic bottles only, the median TAT was shortened by 9 h when samples were incubated in the Virtuo system compared to Bactec FX \( P < 0.0001 \), while no statistically significant difference was observed for anaerobic bottles. When analyzing significant organisms only, the median TAT for samples incubated in the Virtuo system was 22.3 h, and that for samples incubated in the Bactec FX system was 23.0 h \( P > 0.05 \).

For patients identified as being more likely to have poor outcomes typical of sepsis by a quick sequential organ failure assessment (qSOFA) score of \( \geq 2 \) (respiratory rate of 22 breaths per minute or higher, altered mental status, or systolic blood pressure of 100 mm Hg or lower) \( 10 \), a reduction in the TTD was statistically significant in favor of Virtuo.

The median time to pathogen identification (time to ID) and time to AST results were not statistically significantly different between groups when all bottle types were pooled (46.9 h for Virtuo and 46.5 h for Bactec FX \( P = 0.1921 \)) for time to ID; 58.1 h for Virtuo and 58.5 h for Bactec FX \( P = 0.33 \)) for time to AST results). However, when comparing only aerobic bottles, the median time to ID and the median time to AST results were reduced by 6.7 h and 6.6 h, respectively, when samples were incubated in the Virtuo system (median times to ID of 45.5 h for Virtuo and 52.2 h for Bactec FX \( P < 0.0001 \); median times to AST results of 54.4 h for Virtuo and 61.0 h for Bactec FX \( P < 0.0001 \)).

When considering patients with previous antimicrobial treatment, the TTD was significantly lower in the Virtuo arm for all bottle types. The median TTD was 8.7 h lower for aerobic bottles using Virtuo, while for anaerobic bottles, no significant differences were observed (Table 3 and Fig. 3B and C). For specific antibiotics, there was a shorter
TTD for carbapenems and piperacillin-tazobactam with Virtuo. The first-line therapy antibiotics combined (amoxicillin-clavulanate, piperacillin-tazobactam, and carbapenems) showed a median TTD that was 11.2 (22.8 – 11.6) h shorter for samples incubated in the Virtuo system (P = 0.0003). Furthermore, the median TTD in this group was 15.6 (27.2 – 11.6) h shorter when considering aerobic bottles only (P < 0.0001).

**Workflow efficiency and hands-on time.** The mean times for loading each bottle by technicians were 7.28 and 1.32 s per bottle for Bactec FX and Virtuo, respectively. The mean times for unloading negative bottles were 1.89 s/bottle for Bactec FX and 0 for Virtuo, as the latter system automatically discards negative bottles. Nevertheless, for unloading positive bottles, Bactec FX demanded a mean time of 5.72 s/bottle, while Virtuo required 9.86 s/bottle. We had a median of 110 bottles loaded per day, with a positivity rate of 17%. According to our demand and positivity rate, also considering the time employed for maintenance, the hands-on time was shortened by 15 min per day when using Virtuo compared to Bactec FX (Table 4). Moreover, the number of manual steps when handling the bottles was reduced by 7 when using Virtuo compared to Bactec FX, with fewer manual steps to load bottles, unload negative bottles, and unload positive bottles (Fig. 4).

**DISCUSSION**

The time to inform a blood culture result has been reduced in recent years by the implementation of mass spectrometry (matrix-assisted laser desorption ionization–time of flight [MALDI-TOF]) and molecular approaches for species identification and the introduction of rapid AST directly from positive blood cultures. However, these novel rapid methods should also be accompanied by logistic improvements in the pre- and postanalytics so that the total time from the patient entering the hospital to reporting is reduced (11). In this clinical diagnostic trial, we focused on possible differences that could impact the time to detection before the microbiological analytical steps are done, including BC incubation.

Previous studies have shown a higher positivity rate or shorter TTD for Virtuo than for other automated incubation systems, but those studies were conducted either with a “before-and-after” design (12, 13), with spiked bottles (14, 15), or by duplicating samples in either aerobic or anaerobic bottle types (16, 17).

To our knowledge, we report the first clinical diagnostic study of this scale in a “real-world” setting with a crossover design comparing two automatic blood culture incubators using samples from patients with a suspected diagnosis of bacteremia/sepsis, as opposed to spiked vials. Our study design mimics that of clinical trials performed for drug marketing authorization, but patient randomization was replaced with the

### TABLE 1 Time to detection

| Sample type        | Median TTD (h) (IQR) | P value* |
|--------------------|----------------------|----------|
|                    | Virtuo               | Bactec FX|          |
| All positive       | 15.2 (9.6–21.5)      | 16.7 (10.6–25.4) | <0.0001 |
| Aerobic            | 15.2 (10.2–18.9)     | 19.0 (13.6–27.0) | <0.0001 |
| Anaerobic          | 15.3 (8.9–25.9)      | 12.8 (9.6–22.3)  | 0.7503  |
| Contaminants       | 18.9 (15.5–26.5)     | 22.3 (18.4–33.1) | <0.0001 |
| Aerobic            | 17.2 (15.0–21.0)     | 21.3 (18.1–27.8) | <0.0001 |
| Anaerobic          | 24.8 (19.3–34.8)     | 26.2 (20.2–49.2) | 0.0202  |
| Significant organisms | 10.6 (8.2–17.0)     | 11.6 (9.3–17.5)  | 0.0060  |
| Aerobic            | 11.2 (8.7–16.7)      | 14.9 (10.4–25.1) | <0.0001 |
| Anaerobic          | 10.0 (8.0–17.4)      | 10.7 (8.9–14.6)  | 0.7168  |

*Statistically significant values are indicated in boldface type.
crossover design. With this approach, the patient characteristics in both arms were similar, avoiding potential biases that might affect the results and the need for duplicate samples.

The proportion of positive results was significantly higher for the samples incubated in the Virtuo system (18.2% versus 15.5% \( P = 0.0003 \)), with similar numbers of false-positive results for both arms, although there were no significant differences when excluding the contaminating isolates \( P = 0.0519 \). In a previous report, there was no statistical difference in recovery rates based on the overall concentration of microorganisms between the two BC systems (18).

Our primary outcome, TTD, was significantly shorter for the samples incubated in the Virtuo system for all bottles, with a median difference of 1.4 h. These results are in concordance with those of a previous study where the TTD for spiked samples was significantly shorter for aerobic and anaerobic bottles incubated in the Virtuo system (medians of 11.6 h and 10.1 h, respectively) than with Bactec FX (medians of 13.5 h and 12.2 h, respectively) (19). The TTD was also reported to be shorter for seeded bottles incubated in the Virtuo system, with 72.7% of organisms having a significantly shorter TTD for Virtuo than the ones incubated in the Bactec FX system (20).

In our study, this difference was due mostly to the reduced TTD for the aerobic bottles (difference in the median TTD of 3.8 h). This is likely related to a number of causes, but analysis of patients who were treated with antimicrobials prior to blood culture suggests that better neutralization may be one of them. The TTD is significantly shorter...
### TABLE 2 Time to detection and turnaround time by patient characteristics

| Characteristic | Virtuo | Bactec FX | Subgroup analysis for positive extraction with TAT available |
|---------------|--------|-----------|-------------------------------------------------------------|
|               | No. of positive extractions | Median TTD (h) | No. of positive extractions with TAT available | Median TTD (h) | Median TAT (h) | No. of extractions with TAT available | Median TTD (h) | Median TAT (h) |
| Overall       | 852    | 15.3      | 782               | 16.7*             | 842               | 15.4                  | 26.0                 | 767               | 16.9*             | 28.4*             |
| Ward          |        |           |                   |                   |                   |                       |                      |                   |                   |                   |
| Stratum 1 (ED)| 697    | 14.8      | 619               | 16.0*             | 687               | 15.0                  | 25.5                 | 609               | 16.3*             | 27.8*             |
| Stratum 2 (other wards) | 155    | 17.0      | 163               | 19.2*             | 155               | 17.0                  | 27.7                 | 158               | 19.2*             | 31.5*             |
| Bottle detected first* | | | | | | | | | | |
| Aerobic       | 453    | 15.4      | 378               | 19.2*             | 445               | 15.2                  | 25.5                 | 377               | 19.1*             | 35.0*             |
| Anaerobic     | 399    | 15.3      | 404               | 12.6              | 397               | 15.4                  | 26.8                 | 390               | 12.8              | 24.5              |
| Gram stain result | | | | | | | | | | |
| Gram negative | 261    | 9.6       | 258               | 10.2              | 257               | 9.5                   | 21.7                 | 254               | 10.3*             | 20.8              |
| Gram positive | 553    | 17.4      | 483               | 20.0*             | 549               | 17.7                  | 32.4                 | 477               | 19.9*             | 36.6*             |
| Organism type |        |           |                   |                   |                   |                       |                      |                   |                   |                   |
| Contaminant   | 352    | 18.9      | 302               | 22.3*             | 347               | 18.9                  | 38.9                 | 296               | 22.4*             | 41.0*             |
| Significant organism | 500    | 10.6      | 480               | 11.6*             | 495               | 10.7                  | 22.4                 | 471               | 11.6*             | 23.0              |
| Hospital-acquired infection | | | | | | | | | | |
| No            | 737    | 14.9      | 680               | 16.4*             | 727               | 15.0                  | 25.6                 | 670               | 16.6*             | 28.4*             |
| Yes           | 114    | 18.4      | 95                | 18.6*             | 114               | 18.4                  | 30.3                 | 90                | 18.4*             | 27.7              |
| Infection acquired <90 days from previous discharge | | | | | | | | | | |
| No            | 655    | 15.4      | 574               | 16.7*             | 649               | 15.5                  | 26.7                 | 565               | 16.9*             | 30.4*             |
| Yes           | 196    | 14.6      | 201               | 16.3*             | 192               | 14.7                  | 24.7                 | 195               | 16.3*             | 27.0*             |
| Specific organism(s) | | | | | | | | | | |
| CoNS          | 62     | 15.4      | 39                | 17.1              | 61                | 15.4                  | 30.2                 | 38                | 17.6              | 26.6              |
| Escherichia coli | 162  | 8.5       | 169               | 9.6*              | 158               | 8.5                   | 18.1                 | 165               | 9.6*              | 19.0              |
| Klebsiella pneumoniae | 48     | 9.6       | 29                | 9.2               | 44                | 9.9                   | 20.1                 | 25                | 9.2               | 21.3              |
| Staphylococcus aureus | 55     | 14.7      | 48                | 15.6              | 53                | 14.8                  | 22.0                 | 48                | 15.6              | 34.7*             |
| qSOFA score (significant organisms only) | | | | | | | | | | |
| 0             | 286    | 10.8      | 256               | 11.5              | 282               | 10.9                  | 22.5                 | 250               | 11.5              | 22.9              |
| 1             | 137    | 10.2      | 143               | 11.1              | 132               | 10.6                  | 21.7                 | 141               | 11.2              | 23.5              |
| ≥2            | 58     | 9.9       | 65                | 11.4*             | 58                | 9.9                   | 22.3                 | 61                | 12.3*             | 20.8              |

*α, P < 0.05 for Virtuo versus Bactec FX.

*For samples with no record of the time at which the Gram stain result was reported, the TAT was not calculated.

*One culture for Virtuo was missing bottle type data for two extractions. Seven cultures had aerobic and anaerobic bottles positive at the same time. They are included in both the aerobic and anaerobic portions of the table. ED, emergency department; CoNS, coagulase-negative staphylococci; h, hours.
for bottles from subjects with previous treatment with antimicrobials (11.4 h for Virtuo versus 15.9 h for Bactec FX \(P \leq 0.0001\)) and is shorter but not statistically significant for samples from patients without previous antimicrobial treatment (10.2 h for Virtuo versus 10.9 h for Bactec FX \(P = 0.2264\)). Previous publications report that over 40% of inpatients are administered antibiotics before blood collection for culture (21–23). In the present study, 25% of the samples positive for a significant organism were extracted after antimicrobial treatment was initiated. For these samples, the TTD was shorter for aerobic bottles, with a difference in the median TTD of 8.7 h (10.9 h for Virtuo versus 19.6 h for Bactec FX \(P < 0.0001\)), in favor of Virtuo. According to a previous study with spiked blood culture bottles (24), this difference for aerobic bottles could be explained by the better neutralization of antibiotics.

Regarding the workflow efficiency, the hands-on time was reduced by 15 min/day when using Virtuo, and the number of steps required to handle the bottles was reduced from 11 to 4, showing an optimization of preanalytical resources that can impact the results. These calculations are based on the number of bottles loaded per day and the proportions of positive/negative results in our laboratory. The time difference would be greater with a larger number of bottles loaded per day.

Our study has several limitations. First of all, molecular analysis was not performed for the false-positive samples to determine any uncultivable or fastidious organisms. However, the percentages of false-positive results were low and similar in both arms (20% for Virtuo and 17% for Bactec FX). Second, for logistic reasons, it was not possible to include all hospital wards from our institution, but with this sampling, we were able to include 90% of all blood cultures in the hospital. Third, the trial was performed in a single center.

The introduction of any improvement in the time to the detection of a positive blood culture should always be accompanied by effective logistics in the pre- and postanalytic steps. The “microbiologists” (11), a term introduced by Lamy et al., are meant to include

### TABLE 3 Time to detection by previous antibiotic treatment

| Previously administered antimicrobial(s) | Type of bottle | No. of extractions; median TTD (h) (IQR) | Virtuo | Bactec FX | \( P \) valuea |
|------------------------------------------|---------------|---------------------------------------------|--------|----------|---------------|
| Any antimicrobial                        | All           | 129; 11.4 (9.0–20.8)                        | 116; 15.9 (10.9–31.7) | \( 0.0001 \) |
|                                          | Aerobic       | 63; 10.9 (9.1–18.6)                        | 63; 19.6 (12.6–45.6) | \( <0.0001 \) |
|                                          | Anaerobic     | 68; 11.5 (8.6–22.5)                        | 53; 11.7 (10.2–20.1) | 0.6749       |
| No antimicrobial                         | All           | 369; 10.2 (8.0–15.8)                        | 364; 10.9 (8.9–15.1) | 0.2254       |
|                                          | Aerobic       | 177; 11.5 (8.54–16.0)                      | 121; 11.9 (10.0–18.2) | 0.0572       |
|                                          | Anaerobic     | 192; 9.7 (7.7–15.4)                        | 245; 10.3 (8.8–13.6) | 0.4381       |
| Carbapenems                              | All           | 24; 18.4 (11.6–21.7)                       | 28; 31.2 (16.8–54.6) | \( 0.0016 \) |
|                                          | Aerobic       | 17; 16.8 (10.9–22.3)                       | 20; 34.2 (16.8–69.2) | \( 0.0052 \) |
|                                          | Anaerobic     | 7; 19.9 (13.7–21.2)                        | 8; 29.7 (18.8–34.1) | \( 0.0485 \) |
| Cephalosporins                           | All           | 14; 11.3 (10.1–32.3)                       | 23; 13.6 (9.7–19.4) | 0.8978       |
|                                          | Aerobic       | 9; 10.5 (9.9–15.9)                         | 10; 15.0 (9.7–34.7) | 0.2175       |
|                                          | Anaerobic     | 6; 21.4 (10.4–44.5)                        | 13; 12.1 (10.6–16.9) | 0.3180       |
| Piperacillin-tazobactam                  | All           | 25; 9.5 (8.8–11.4)                         | 26; 19.4 (12.6–39.7) | \( <0.0001 \) |
|                                          | Aerobic       | 13; 10.8 (9.1–12.0)                        | 22; 18.0 (12.6–42.9) | \( 0.0043 \) |
|                                          | Anaerobic     | 12; 9.1 (8.4–10.9)                         | 4; 21.5 (17.6–25.3) | NA           |
| Amoxicillin-clavulanic acid              | All           | 15; 10.2 (8.0–36.0)                        | 17; 11.6 (10.8–18.7) | 0.7764       |
|                                          | Aerobic       | 4; 9.5 (5.9–49.3)                         | 5; 30.9 (17.2–40.6) | NA           |
|                                          | Anaerobic     | 12; 8.7 (11.5–35.5)                        | 12; 11.0 (10.5–14.6) | 0.6411       |
| First-line therapy (carbapenems, piperacillin-tazobactam, or amoxicillin-clavulanic acid) | All | 64; 11.6 (8.9–20.5) | 69; 22.8 (11.6–39.7) | \( 0.0003 \) |
|                                          | Aerobic       | 34; 11.6 (9.1–20.4)                        | 45; 27.2 (15.6–48.6) | \( <0.0001 \) |
|                                          | Anaerobic     | 31; 11.4 (8.5–20.6)                        | 24; 16.3 (10.9–27.4) | 0.1461       |

aStatistically significant values are indicated in boldface type. NA, not applicable due to the limited sample size.
all of these aspects of the logistics in microbiology: the time to start the incubation of BC vials, the transport time, rapid communication of results, infectious disease consultation, or, even better, an antibiotic stewardship program. We have demonstrated different options to shorten the TTD, TAT, time to ID, and time to AST results, with changes in the automatic incubator, but these differences may not have all of their potential impacts if all of the other aspects of the diagnosis of bloodstream infection are not optimized. In the current study, we reported an overall median TAT ranging from 26.2 h to 28.3 h, suggesting that the time between positivity and reporting of Gram stain results is 10 h. In the analysis plan, the TAT was examined at the extraction level, including contaminants and multiple positive extractions during the same bacteremia episode. For these samples, the report is not immediate and might be delayed before validation. This may have led to an overall overestimation of the TAT. The enhancement of the workflow efficiency and the reduction in the hands-on time accomplished by using Virtuo could be part of the microbiologistics improvements.

In summary, we have shown in a real-world setting that Virtuo provides shorter TTD and TAT than Bactec FX and that the TTD for aerobic bottles is even shorter for patients who have received antimicrobials before blood culture extraction. This could have an important effect on the faster identification of causative microorganisms of BSIs and antimicrobial stewardship.
MATERIALS AND METHODS

Study design. We compared the performance of BacT/Alert Virtuo (bioMérieux, France) to that of the Bactec FX instrument (BD, USA) with a prospective crossover diagnostic clinical trial. We included 3,625 nonpediatric patients (≥16 years old) suspected of having bacteremia/fungemia who were localized in different wards of Ramón y Cajal Hospital (Madrid, Spain): the emergency department (ED), internal medicine, hematology, surgical intensive care unit (ICU), medical ICU, general surgery, and infectious diseases. Since 70% of all blood cultures of the hospital are routinely ordered from the ED, we divided the patients into two strata: stratum 1 was assigned to the ED, and stratum 2 included all other wards. Initially, each stratum was randomly assigned to one of the incubators and then alternated every 2 weeks for 6 months (from November 2018 to April 2019).

BC testing was performed using Bactec Plus Aerobic/F bottles (aerobic bottles) and Bactec Lytic/10 Anaerobic/F bottles (anaerobic bottles) incubated in the Bactec FX system or using BacT/Alert FA Plus

| Parameter                             | Bactec FX | Virtuo |
|---------------------------------------|-----------|--------|
| Bottles loaded/day (n = 110)          | 7.26 ± 3.7| 1.32 ± 0.5 |
| Positive unloaded bottles/day (17%)   | 5.72 ± 2.22| 9.86 ± 2.88 |
| Negative unloaded bottles/day (83%)  | 1.89 ± 1.32| 0 |
| Daily maintenance                     | 181       | NAa    |
| Waste bin change every 72 bottles     | NA        | 8.48 ± 2 |
| Wkly cleaning of conveyor             | NA        | 0.14 |
| Total                                 | 21.02     | 3.02   |

| Parameter                             | Bactec FX | Virtuo |
|---------------------------------------|-----------|--------|
| Positive unloaded bottles/day (17%)   | 1.78      | 3.07   |
| Negative unloaded bottles/day (83%)  | 2.88      | 0   |
| Daily maintenance                     | 3.02      | NA    |
| Waste bin change every 72 bottles     | 2.88      | 3.07   |
| Wkly cleaning of conveyor             | 12.25 ± 2.63| 0.20 |
| Total                                 | 5.84      | −0.20  |

aNA, not applicable.

TABLE 4 Hands-on-time measurements

FIG 4 Number of steps required to process samples in each automated blood culture incubator. The steps are grouped for the following processes: loading of all bottles, unloading of negative samples, and unloading of positive samples. Unloading of negative bottles from the Virtuo system is automated; therefore, there are zero steps.
TABLE 5 Summary of samples and types of bottles analyzed

| Parameter                          | Value for system | P value<sup>c</sup> |
|-----------------------------------|------------------|---------------------|
| No. of blood culture sets         | 2,391            | 2,588               |
| No. of extractions evaluated (%)  | 4,797            | 5,160               |
| All bottles negative             | 3,923 (81.8)     | 4,361 (84.5)        |
| At least 1 bottle positive        | 874 (18.2)       | 799 (15.5)          |
| No. of aerobic bottles analyzed/set (%) | 3 (0.1) | 7 (0.3) |
| 0                                | 90 (3.8)         | 125 (4.8)           |
| 1                                | 2,219 (92.8)     | 2,390 (92.4)        |
| 2                                | 79 (3.3)         | 66 (2.6)            |
| No. of anaerobic bottles analyzed/set (%) | 5 (0.2) | 8 (0.3) |
| 0                                | 78 (3.3)         | 124 (4.8)           |
| 1                                | 2,229 (93.2)     | 2,391 (92.4)        |
| 2                                | 79 (3.3)         | 65 (2.5)            |
| No. of 1st bottles detected as positive (%) | 466 (53.4) | 391 (48.9) |
| Aerobic                          | 402 (46.1)       | 405 (50.7)          |
| Both simultaneously              | 3 (0.3)          | 3 (0.4)             |
| Unknown                          | 2 (0.2)          | 0                   |
| No. of positive samples/total no. of samples (%) | 874/4,797 (18.2)<sup>a</sup> | 799/5,160 (15.5) | 0.0003 |
| No. of positive samples/total no. of samples (%) excluding false positives | 854/4,797 (17.8) | 782/5,160 (15.2) | 0.0003 |
| No. of false-positive samples     | 20               | 17                  |
| No. of samples with contaminant   | 354              | 302                 |
| No. of samples with significant organism | 502            | 480                 |
| No. of positive aerobic samples/total no. of aerobic samples (%) | 470/4,765 (9.9) | 394/5,103 (7.7) | 0.0002 |
| No. of positive aerobic samples/total no. of aerobic samples (%) excluding false positives | 459/4,765 (9.6) | 381/5,103 (7.5) | 0.0001 |
| No. of false-positive samples     | 13               | 13                  |
| No. of samples with contaminant   | 217              | 197                 |
| No. of samples with significant organism | 240            | 184                 |
| No. of positive anaerobic samples/total no. of anaerobic samples (%) | 406/4,773 (8.5) | 408/5,101 (8.0) | 0.3593 |
| No. of positive anaerobic samples/total no. of anaerobic samples (%) excluding false positives | 399/4,773 (8.4) | 404/5,101 (7.9) | 0.4246 |
| No. of false-positive samples     | 7                | 4                   |
| No. of samples with contaminant   | 137              | 106                 |
| No. of samples with significant organism | 262            | 298                 |

<sup>a</sup>Seven cultures had aerobic and anaerobic bottles positive at the same time. They are included in both the aerobic and anaerobic portions of the table.

<sup>b</sup>One culture in the Virtuo system was missing bottle type data for two extractions.

<sup>c</sup>Statistically significant values are indicated in boldface type.
microorganism was not considered to be a contaminant and if this was the first bacteremia episode for that patient.

**Time measurement definitions.** The following definitions were used (Fig. 5): (i) time to detection (TTD), the time from the loading of the sample into the automated blood culture incubator to a positivity signal for the first bottle, either aerobic or anaerobic (if the anaerobic and aerobic bottles were positive at the same time, both were included); (ii) turnaround time (TAT), the interval from loading of the specimen into the automated blood culture incubator to the reporting of the Gram stain results to the clinician; (iii) time to identification (time to ID), the time from the loading of the sample into the automated blood culture incubator to identification; and (iv) the time to AST results, the time from the loading of the sample into the automated blood culture incubator to the final AST report.

**Data analysis.** The time for loading into the incubators, TTD, TAT, time to ID, and time to AST results were retrieved from the laboratory’s information system and patient clinical charts and recorded in an electronic database.

As a general rule, the following microorganisms, when present in a single sample with no other cultures positive for the same organism within 96 h, were considered contaminants: coagulase-negative staphylococci (CoNS) with the exception of *Staphylococcus lugdunensis*, *Propionibacterium* spp., *Bacillus* spp. different from *Bacillus anthracis*, *Corynebacterium* spp. (diphtheroids), *Aerococcus*-like organisms, *Micrococcus* spp., viridans group streptococci, *Neisseria* spp. excluding *Neisseria gonorrhoeae* or *N. meningitidis*, and *Streptomyces* spp. Furthermore, all positive results were reviewed by clinical microbiologists and medical doctors along with the patient’s clinical history to differentiate contaminants from significant microorganisms.

Antibiotic treatment was recorded for all patients considered to have a significant isolate producing bacteremia/fungemia. Previous antibiotic treatment was defined as any antimicrobial administered in the 5 days preceding sample extraction.

False-positive results were defined as bottles that signaled “positive” by the instruments but with no growth after subculture.

**Workflow efficiency and hands-on-time measurement.** The standard time (hands-on time) and the number of steps required when processing either a negative or a positive BC with the respective automated systems were measured, including all of the manipulations performed by the technician, according to the instructions provided by the instrument user manuals.

Two technicians were observed from 8 to 9 a.m. and from 1 to 3 p.m. Monday to Friday for 4 weeks. Time was measured as follows:

- **Loading time for one bottle**
  - Bactec FX: starting from the technician being located in front of the machine and finishing when the drawer is closed.
  - Virtuo: starting from the technician being located in front of the machine and finishing when the bottle is placed on the conveyor.

- **Unloading time for one positive bottle**
  - Bactec FX: starting from the technician being located in front of the machine and finishing when the drawer is closed.
  - Virtuo: starting from the technician pressing the “remove positive bottle” icon and finishing when the bottle is removed.

- **Unloading time for one negative bottle**
  - Bactec FX: starting from the technician being located in front of the machine and finishing when the drawer is closed.
  - Virtuo: none.

Sampling was done to estimate the minimum number of observations to have a statistically relevant result for the hands-on-time comparison.
The technicians were observed for a period of 20 days until we reached the following number of observations:

- Loading BacT/Alert Virtuo bottles, 340 observations
- Unloading BacT/Alert Virtuo bottles (positive), 181 observations
- Unloading BacT/Alert Virtuo bottles (negative)
- Loading Bactec FX bottles, 431 observations
- Unloading Bactec FX bottles (positive), 101 observations
- Unloading Bactec FX bottles (negative), 233 observations

The mean time employed and the standard deviation (SD) were calculated, and the total time employed per day was estimated for a mean activity of 110 bottles incubated in each instrument per day.

**Statistical analysis.** Categorical variables were compared using a chi-squared test. Continuous variables were compared using a t test. Time-to-event variables were compared using a Tarone-Ware test. The most common statistics used to measure the differences between time-to-event curves are the log rank test. The log rank test emphasizes primarily the differences between the curves at the longest times to event, while the Wilcoxon test emphasizes those at the shortest. The Tarone-Ware test used here looks for symmetry in the behaviors of the curves around the median.

All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA). P values of ≤0.05 were taken to indicate significant differences.

**ACKNOWLEDGMENTS**

We acknowledge the excellent work from our technicians Sergio Talens Pacheco, Miriam Cuesta, and Maria Isabel Moya Medina and nurses Nuria Molina and Clara Ramírez Gómez. We also thank Patricia de Saint Jean, Victoria González and Yohann Bala from bioMérieux for their suggestions for the study design and data analysis.

R.C. and A.V.H. conceived and designed the study. R.C. obtained funding and supervised the study. A.V.H., J.A.d.C.P., J.L.C.-C., M.J.C.I., and M.A.M. acquired the data. A.V.H. and R.C. analyzed and interpreted the data. R.B. did the statistical analysis. A.V.H. drafted the manuscript. All authors critically revised the manuscript for important intellectual content.

R.C. has participated in educational programs supported by bioMérieux and BD. A.V.H. has participated in educational programs supported by bioMérieux. R.B. is senior lead biomathematician at bioMérieux. All other authors declare no competing interests.

The study was partially funded by bioMérieux (France) and the Instituto de Salud Carlos III, Spain (REIPI-RD16/0016/0011 and CIBERINFEC-CB21/13/00084).

**REFERENCES**

1. Fleischmann C, Scherag A, Adhikari NKJ, Hartog CS, Tsaganos T, Schlattmann P, Angus DC, Reinhart K. International Forum of Acute Care Trials. 2016. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med 193:259–272. https://doi.org/10.1164/rcrm.201504-0710OC.

2. Walkey AJ, Lagu T, Linenauer PK. 2015. Trends in sepsis and infection sources in the United States. A population-based study. Ann Am Thorac Soc 12:216–220. https://doi.org/10.1513/AnnalsATS.201411-498BC.

3. Winters BD, Eberlein M, Leung J, Needham DM, Pronovost PJ, Sevransky JE. 2010. Long-term mortality and quality of life in sepsis: a systematic review. Crit Care Med 38:1276–1283. https://doi.org/10.1097/CCM.0b013e3181d8cc1d.

4. Rahmel T, Schmitz S, Nowak H, Schepanek K, Bergmann L, Hörter S, Peters J, Adamzik M. 2020. Long-term mortality and outcome in hospital survivors of septic shock, sepsis, and severe infections: the importance of aftercare. PLoS One 15:e0228952. https://doi.org/10.1371/journal.pone.0228952.

5. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Talberg L, Gurka D, Kumar A, Cheang M. 2006. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589–1596. https://doi.org/10.1097/01.CCM.0000227.17961.75225.E9.

6. Whiles BB, Deis AS, Simpson SQ. 2017. Increased time to initial antimicrobial administration is associated with progression to septic shock in severe sepsis patients. Crit Care Med 45:623–629. https://doi.org/10.1097/CCM.0000000000002262.

7. Lamy B, Dargère S, Arendrup MC, Parienti J-J, Tattevin P. 2016. How to optimize the use of blood cultures for the diagnosis of bloodstream infections? A state-of-the art. Front Microbiol 7:697. https://doi.org/10.3389/fmicb.2016.00697.

8. Munson EL, Diekema DJ, Beekmann SE, Chapin KC, Doern GV. 2003. Detection and treatment of bloodstream infection: laboratory reporting and antimicrobial management. J Clin Microbiol 41:495–497. https://doi.org/10.1128/JCM.41.1.495-497.2003.

9. Beuving J, Wolffs PFG, Hansen WLJ, Stobberingh EE, Bruggeman CA, Kessels A, Verbon A. 2015. Impact of same-day antibiotic susceptibility testing on time to appropriate antibiotic treatment of patients with bacteraemia: a randomised controlled trial. Eur J Clin Microbiol Infect Dis 34:831–838. https://doi.org/10.1007/s10096-014-2299-0.

10. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche J-D, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. 2016. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315:801–810. https://doi.org/10.1001/jama.2016.0287.

11. Lamy B, Sundqvist M, Idelevich EA, ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES). 2020. Bloodstream infections—standard and progress in pathogen diagnostics. Clin Microbiol Infect 26:142–150. https://doi.org/10.1016/j.cmi.2019.11.017.

12. Chavez MA, Muniglia S, Burnham CA, Yarbrough ML, Warren DK. 2020. Clinical performance evaluation of Virtuo blood culture system in a tertiary care hospital. Open Forum Infect Dis 7(Suppl 1):S383. https://doi.org/10.1093/ofid/ofaa399.844.

13. Le Guern T, Trécat M, Loize C, Duployez C, Wallez F, Dessein R. 2021. Comparison of time-to-positivity between two blood culture systems: a detailed analysis down to the genus-level. Eur J Clin Microbiol Infect Dis 40:1399–1404. https://doi.org/10.1007/s10096-021-04175-9.
14. Totty H, Ullery M, Spontak J, Viray J, Adamik M, Katzin B, Dunne WM, Deol P. 2017. A controlled comparison of the BacT/ALERT 3D and VIRTUO microbial detection systems. Eur J Clin Microbiol Infect Dis 36:1795–1800. https://doi.org/10.1007/s10096-017-2994-8.

15. Yarbrough ML, Wallace MA, Burnham CAD. 2021. Comparison of microorganism detection and time to positivity in pediatric and standard media from three major commercial continuously monitored blood culture systems. J Clin Microbiol 59:e00429-21. https://doi.org/10.1128/JCM.00429-21.

16. Jacobs MR, Mazzulli T, Hazen KC, Good CE, Abdelhamed AM, Lo P, Shum B, Roman KP, Robinson DC. 2017. Multicenter clinical evaluation of BacT/Alert Virtuo blood culture system. J Clin Microbiol 55:2413–2421. https://doi.org/10.1128/JCM.00307-17.

17. Kim SC, Lee S, Kim S, Cho OH, Park H, Yu SM. 2019. Comparison of clinical performance between BacT/Alert Virtuo and BacT/Alert 3D blood culture systems. Ann Lab Med 39:278–283. https://doi.org/10.3343/alm.2019.39.3.278.

18. Park J, Han S, Shin S. 2017. Comparison of growth performance of the BacT/ALERT VIRTUO and BACTEC FX blood culture systems under simulated bloodstream infection conditions. Clin Lab 63:39–46. https://doi.org/10.7754/Clin.Lab.2016.160502.

19. Menchinelli G, Liotti FM, Fiori B, De Angelis G, D’Inzeo T, Giordano L, Postesarò B, Sabbatucci M, Sanguinetti M, Spanu T. 2019. In vitro evaluation of BACT/ALERT VIRTUO, BACT/ALERT 3D, and BACTEC FX automated blood culture systems for detection of microbial pathogens using simulated human blood samples. Front Microbiol 10:222. https://doi.org/10.3389/fmicb.2019.00221.

20. Somily AM, Habib HA, Torchyan AA, Sayyed SB, Absar M, Al-Aqeel R, Binkhamis AK. 2018. Time-to-detection of bacteria and yeast with the BACTEC FX versus BacT/Alert Virtuo blood culture systems. Ann Saudi Med 38:194–199. https://doi.org/10.5144/0256-4947.2018.194.

21. Roh KH, Kim JY, Kim HN, Lee HJ, Sohn JW, Kim MJ, Cho Y, Kim YK, Lee CK. 2012. Evaluation of BACTEC Plus aerobic and anaerobic blood culture bottles and BacT/Alert FAN aerobic and anaerobic blood culture bottles for the detection of bacteremia in ICU patients. Diagn Microbiol Infect Dis 73:239–242. https://doi.org/10.1016/j.diagmicrobio.2012.03.022.

22. Ziegler R, Johnscher I, Martus P, Lenhardt D, Just HM. 1998. Controlled clinical laboratory comparison of two supplemented aerobic and anaerobic media used in automated blood culture systems to detect bloodstream infections. J Clin Microbiol 36:657–661. https://doi.org/10.1128/JCM.36.3.657-661.1998.

23. Pohlman JK, Kirkley BA, Easley KA, Basille BA, Washington JA. 1995. Controlled clinical evaluation of BACTEC Plus Aerobic/F and BacT/Alert Aerobic FAN bottles for detection of bloodstream infections. J Clin Microbiol 33:2856–2858. https://doi.org/10.1128/jcm.33.11.2856-2858.1995.

24. Chung Y, Kim H-I, Han M, Kim HS, Kim H-S, Song W, Kim J-S. 2019. A comparative evaluation of BACT/ALERT FA PLUS and FN PLUS blood culture bottles and BD BACTEC Plus Aerobic and Anaerobic blood culture bottles for antimicrobial neutralization. Eur J Clin Microbiol Infect Dis 38:2229–2233. https://doi.org/10.1007/s10096-019-03663-3.

25. López-Pintor JM, Navarro-San Francisco C, Sánchez-López J, García-Caballero A, Loza Fernández de Bobadilla E, Morosini ML, Cantón R. 2019. Direct antimicrobial susceptibility testing from the blood culture pellet obtained for MALDI-TOF identification of Enterobacteriales and Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 38:1095–1104. https://doi.org/10.1007/s10096-019-03498-y.